How may haemoglobin change with cancer treatment?

How may haemoglobin change with cancer treatment?

• A. Haemoglobin is often reduced during chemotherapy.
• B. Haemoglobin always increases with treatment.
• C. Haemoglobin remains unchanged.
• D. Haemoglobin fluctuates unpredictably, with no trend.

Answer: (B)

Cancer therapy often reduces haemoglobin because chemotherapy suppresses the bone marrow’s ability to produce red blood cells. This myelosuppressive effect is a common side effect of many regimens, especially during the early cycles, so haemoglobin levels frequently fall, leading to anemia. Other contributing factors include inflammation from cancer, nutritional deficiencies, and possible iron losses or bleeding during treatment. Because red blood cell production is impaired while treatment is ongoing, haemoglobin tends to be lower in the active phase of therapy. Over time, as treatment cycles progress and the marrow recovers, haemoglobin can rise again, and interventions such as transfusions or addressing deficiencies can help manage anemia. However, it is not guaranteed to increase with treatment and may remain low or fluctuate depending on the specific regimen, patient factors, and how well the marrow recovers. In short, the most typical pattern is a reduction in haemoglobin during chemotherapy, with potential recovery later or with supportive care, rather than a guaranteed or universal increase.

Cancer therapy often reduces haemoglobin because chemotherapy suppresses the bone marrow’s ability to produce red blood cells. This myelosuppressive effect is a common side effect of many regimens, especially during the early cycles, so haemoglobin levels frequently fall, leading to anemia. Other contributing factors include inflammation from cancer, nutritional deficiencies, and possible iron losses or bleeding during treatment. Because red blood cell production is impaired while treatment is ongoing, haemoglobin tends to be lower in the active phase of therapy.

Over time, as treatment cycles progress and the marrow recovers, haemoglobin can rise again, and interventions such as transfusions or addressing deficiencies can help manage anemia. However, it is not guaranteed to increase with treatment and may remain low or fluctuate depending on the specific regimen, patient factors, and how well the marrow recovers. In short, the most typical pattern is a reduction in haemoglobin during chemotherapy, with potential recovery later or with supportive care, rather than a guaranteed or universal increase.